TGTX JPM 2025 Presentation 1.13.25.pdf

《TGTX JPM 2025 Presentation 1.13.25.pdf》由会员分享，可在线阅读，更多相关《TGTX JPM 2025 Presentation 1.13.25.pdf（21页珍藏版）》请在三个皮匠报告上搜索。

1、FIERCELY FOCUSEDJanuary 2025J.P.Morgan Healthcare Conference 2Forward Looking Safe Harbor StatementThis presentation contains forward-looking statements that involve a number of risks and uncertainties.For those statements,we claim the protection of the safe harbor for forward-looking statements con

2、tained in the Private Securities Litigation Reform Act of 1995.Such forward looking statements include but are not limited to statements regarding expectations for success of our commercial launch and availability of BRIUMVI(ublituximab-xiiy)for relapsing forms of multiple sclerosis(RMS);anticipated

3、 healthcare professional and patient acceptance and use of BRIUMVI for the FDA-approved indications,statements regarding the results of the ULTIMATE I&II Phase 3 studies as well as the long term safety study and BRIUMVI as a potential treatment for RMS and our statements regarding our potential reve

4、nue targets,operating expenses and cash position.Additional factors that could cause our actual results to differ materially include the following:the Companys ability to establish and maintain a commercial infrastructure for BRIUMVI,and to successfully or in the timeframe projected,launch,market an

5、d sell BRIUMVI;the failure to obtain and maintain requisite regulatory approvals,including the risk that the Company fails to satisfy post-approval regulatory requirements,the potential for variation from the Companys projections and estimates about the potential market for BRIUMVI due to a number o

6、f factors,including,further limitations that regulators may impose on the required labeling for BRIUMVI(such as modifications,resulting from safety signals that arise in the post-marketing setting or in the long-term extension study from the ULTIMATE I and II clinical trials);the Companys ability to